{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:09:59Z","timestamp":1770815399663,"version":"3.50.1"},"reference-count":40,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Clinical Toxicology"],"published-print":{"date-parts":[[2016,10,20]]},"DOI":"10.1080\/15563650.2016.1211288","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T11:16:58Z","timestamp":1470395818000},"page":"819-825","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Adverse events related to the new psychoactive substance 3-fluorophenmetrazine \u2013 results from the Swedish STRIDA project"],"prefix":"10.1080","volume":"54","author":[{"given":"Matilda","family":"B\u00e4ckberg","sequence":"first","affiliation":[{"name":"Swedish Poisons Information Centre, Stockholm, Sweden;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Westerbergh","sequence":"additional","affiliation":[{"name":"Swedish Poisons Information Centre, Stockholm, Sweden;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olof","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;"},{"name":"Clinical Pharmacology, Karolinska University Laboratory, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Helander","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;"},{"name":"Clinical Pharmacology, Karolinska University Laboratory, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"key":"CIT0001","unstructured":"EMCDDA. European Drug Report 2015: trends and developments [Internet]. 2015 [cited 2016 Jul]. Available from: http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_239505_EN_TDAT15001ENN.pdf."},{"key":"CIT0002","unstructured":"EMCDDA. EU Drug Markets Report 2016 \u2013 In-depth Analysis [Internet]. 2016 [cited 2016 Jul]. Available from: http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2373\/TD0216072ENN.pdf."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2014.02.022"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2302"},{"key":"CIT0005","unstructured":"EMCDDA. New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015) [Internet]. 2015. Available from: http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_235958_EN_TD0415135ENN.pdf."},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1079325"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1054505"},{"key":"CIT0008","unstructured":"Risk assessments of a various psychoactive substances 1999\u20132015 [Internet]. [cited 2016 Jul] Available from: http:\/\/www.emcdda.europa.eu\/publications-database?f[0]=field_series_type%253Aname%3ARisk%20assessments."},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2016.1139715"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1033630"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.943908"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197010012831410"},{"key":"CIT0013","unstructured":"EMCDDA. The European information system and database on new drugs (EDND) [Internet]. [cited 2016 Apr]. Available from: http:\/\/ednd.emcdda.europa.eu."},{"key":"CIT0014","unstructured":"Blough BE, Rothman R, Landavazo A, et\u00a0al. Phenylmorpholines and analogues thereof 2011. Patent No. US20130203752 A1. Research Triangle Institute, USA; [Internet]. 2011 [cited 2016 April]. Available from: http:\/\/www.google.com\/patents\/US20130203752."},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.3109\/00365513.2013.793817"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.3109\/15563659809028940"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1988.69.5.0699"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2013.04.043"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1089576"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.981823"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.222"},{"key":"CIT0022","unstructured":"L\u00e4kemedelsverkets f\u00f6rteckning I \u00f6ver narkotika (LVFS 2011:10\/HSLF-FS 2015:12) [The Medical Products Agency\u2019s list of provisions on narcotics]; 2015."},{"key":"CIT0023","unstructured":"Flashback \u2013 Thread on 3-FPM [Internet]; [cited 2016 Jul]. Available from: https:\/\/www.flashback.org\/t2452827."},{"key":"CIT0024","unstructured":"Bluelight. [Internet]; [cited 2016 Jul]. Available from: http:\/\/www.bluelight.org\/vb\/content\/."},{"key":"CIT0025","unstructured":"Drugs-forum. [Internet]; [cited 2016 Jul]. Available from: https:\/\/drugs-forum.com\/forum\/index.php."},{"key":"CIT0026","unstructured":"Erowid. [Internet]; [cited 2016 Jul]. Available from: http:\/\/www.erowid.org\/."},{"key":"CIT0027","unstructured":"Flashback \u2013 Thread on 4-FPM. [Internet]; [cited 2016 Jul]. Available from: https:\/\/www.flashback.org\/t2620291."},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1945"},{"key":"CIT0029","unstructured":"BulgaLupum. [Internet]; [cited 2016 April]. Available from: https:\/\/www.bulgalupum.com\/products\/3-FPM."},{"key":"CIT0030","unstructured":"Researchchemist.co.uk. [Internet]; [cited 2016 April]. Available from: http:\/\/researchchemist.co.uk\/research-chemicals\/3f-phenmetrazine\u20133fpm-new."},{"key":"CIT0031","unstructured":"MARTINDALE \u2013 Phenmetrazine Hydrochloride. [Internet]; [cited 2016 April]. Available from: http:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/ND_T\/evidencexpert\/ND_PR\/evidencexpert\/CS\/4E73F8\/ND_AppProduct\/evidencexpert\/DUPLICATIONSHIELDSYNC\/A449E5\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_P\/evidencexpert\/PFActionId\/evidencexpert.IntermediateToDocumentLink?docId=1487-z&contentSetId=30&title=PhenmetrazineHydrochloride&servicesTitle=PhenmetrazineHydrochloride&navResults=relatedMartindale."},{"key":"CIT0032","unstructured":"Thoma O. Processing for the production of substituted morpholines. U.S. Patent No. 2,835,669. U.S. Patent and Trademark Office, Washington DC, USA, 1958."},{"key":"CIT0033","unstructured":"MARTINDALE \u2013 Phendimetrazine Tartrate. [Internet]; [cited 2016 April]. Available from: http:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/ND_T\/evidencexpert\/ND_PR\/evidencexpert\/CS\/7DE5FB\/ND_AppProduct\/evidencexpert\/DUPLICATIONSHIELDSYNC\/6C92DD\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_P\/evidencexpert\/PFActionId\/evidencexpert.IntermediateToDocumentLink?docId=1486-j&contentSetId=30&title=PhendimetrazineTartrate&servicesTitle=Phendimetrazine Tartrate&navResults=relatedMartindale."},{"key":"CIT0034","unstructured":"L\u00e4kemedelsverkets f\u00f6rteckning I \u00f6ver narkotika (LVFS 2011:10) [The Medical Products Agency\u2019s list of provisions on narcotics] [Internet]. 2011. Available from: https:\/\/lakemedelsverket.se\/upload\/lvfs\/LVFS_2011-10.pdf."},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-7368(73)70827-6"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.3109\/15563658809000351"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1016\/0379-0738(89)90142-4"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20236"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1971.tb07187.x"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1007\/BF00246905"}],"container-title":["Clinical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15563650.2016.1211288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T10:56:31Z","timestamp":1598698591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/15563650.2016.1211288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,10,20]]}},"alternative-id":["10.1080\/15563650.2016.1211288"],"URL":"https:\/\/doi.org\/10.1080\/15563650.2016.1211288","relation":{},"ISSN":["1556-3650","1556-9519"],"issn-type":[{"value":"1556-3650","type":"print"},{"value":"1556-9519","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ictx20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ictx20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}